At the 44th Annual J.P. Morgan Healthcare Conference, RxSight CEO Ron Kurtz presented the company’s proprietary Light Adjustable Lens (LAL) platform, emphasizing five years of pioneering 'adjustability' in ophthalmology. Kurtz detailed how post‐implant adjustments using the Light Delivery Device enable surgeons to fine‐tune refractive outcomes, addressing a longstanding unmet need in premium intraocular lenses (IOLs). This unique capability underpins the company’s strategy to capture a larger share of the growing cataract surgery market by offering differentiated patient outcomes.

RxSight reported approximately 300,000 LAL procedures performed to date, supported by a network of 1,100 ophthalmic offices and over 2,500 trained surgeons. The company grew its installed base by nearly 20% in the most recent fiscal year, driving a 12% year‐over‐year increase in procedure volume. With a headcount of about 500 employees and roughly 10% share of the U.S. premium IOL market, RxSight maintains a strong balance sheet bolstered by recent capital raises and cost discipline. The appointment of CFO Mark Wilterding, with deep med‐tech and banking experience, is expected to further reinforce financial planning and capital allocation.

Following the conference appearance and year‐end operational update, RxSight shares surged 14.1% on above‐average trading volume. Despite the rally, consensus earnings estimate revisions have shown a slight downward trend over recent weeks, suggesting that analysts are cautiously monitoring procedure adoption rates and reimbursement dynamics. Investors will be watching upcoming quarterly results for indicators on average revenue per procedure and potential expansion into international markets.